|
|
||||||||||
|
J Am Coll Cardiol, 1999; 33:186-191 © 1999 by the American College of Cardiology Foundation |
a Division of Cardiology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
Manuscript received September 11, 1998; accepted September 24, 1998.
Address for correspondence: Dr. John D. Parker, Mount Sinai Hospital, Division of Cardiology, 600 University Avenue, Suite 1609, Toronto, Ontario, Canada M5G-1X5
jdp{at}inforamp.net
Objectives. We studied the effects of clonidine on cardiac sympathetic activity and left ventricular function in patients with congestive heart failure (CHF).
Background. Sympathetic activation has major prognostic implications in patients with heart failure. Clonidine, an imidazoline and alpha2-receptor agonist, has been shown to cause a reduction in generalized sympathetic activity.
Methods. Nine patients with CHF (left ventricular ejection fraction 22 ± 4% [mean ± SEM]) received a 50 µg and 100 µg bolus of clonidine intravenously. Study measurements included right and left heart hemodynamics, cardiac output, rate of rise in left ventricular peak positive pressure (LV +dP/dt) and tau, along with cardiac and total body norepinephrine spillover. The radiotracer method was used for calculation of norepinephrine spillover.
Results. Right and left heart filling pressures did not change in response to either dose of clonidine. Mean arterial pressure fell after the second dose of clonidine, from 94 ± 8 to 82 ± 6 mm Hg (p < 0.05). The LV + dP/dt was reduced from 737 ± 53 to 629 ± 43 mm Hg/s (p < 0.05). Clonidine also caused a significant increase in tau, as measured by the method of Weiss (65 ± 3 vs. 74 ± 4 ms, p < 0.01) and the direct pressure half-time technique (48 ± 2 vs. 54 ± 3 ms, p < 0.01). Cardiac norepinephrine spillover fell from 121 ± 29 to 52 ± 20 pmol/min in response to 100 µg of clonidine (p < 0.01 vs. control).
Conclusions. Despite a significant fall in arterial pressure, clonidine caused a marked reduction in sympathetic activity directed at the heart. The negative inotropic and lusitropic effects appear to be secondary to this reduction in sympathetic drive. Because increased cardiac and generalized sympathetic activity are strong predictors of an adverse outcome in patients with CHF, the role of centrally active sympathoinhibitory agents in the therapy of CHF deserves further exploration.
| ||||||||||||||||
This article has been cited by other articles:
![]() |
A. Al-Hesayen and J. D. Parker Adverse effects of atrioventricular synchronous right ventricular pacing on left ventricular sympathetic activity, efficiency, and hemodynamic status Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2377 - H2379. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Akers and L. A. Cassis Presynaptic modulation of evoked NE release contributes to sympathetic activation after pressure overload Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2151 - H2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Igawa, T. Nozawa, N. Fujii, B.-i. Kato, H. Asanoi, and H. Inoue Long-term treatment with Low-Dose, but not High-Dose, guanethidine improves ventricular function and survival of rats with heart failure after myocardial infarction J. Am. Coll. Cardiol., August 6, 2003; 42(3): 541 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-s. Liang Sympatholysis and cardiac sympathetic nerve function in the treatment of congestive heart failure J. Am. Coll. Cardiol., August 6, 2003; 42(3): 549 - 551. [Full Text] [PDF] |
||||
![]() |
A. Aggarwal, M. D. Esler, M. J. Morris, G. Lambert, and D. M. Kaye Regional Sympathetic Effects of Low-Dose Clonidine in Heart Failure Hypertension, March 1, 2003; 41(3): 553 - 557. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Floras The "Unsympathetic" Nervous System of Heart Failure Circulation, April 16, 2002; 105(15): 1753 - 1755. [Full Text] [PDF] |
||||
![]() |
G. Grassi, C. Turri, G. Seravalle, G. Bertinieri, A. Pierini, and G. Mancia Effects of Chronic Clonidine Administration on Sympathetic Nerve Traffic and Baroreflex Function in Heart Failure Hypertension, August 1, 2001; 38(2): 286 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Aggarwal, M. D. Esler, F. Socratous, and D. M. Kaye Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1246 - 1251. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shite, E. Dong, H. Kawai, S. Y. Stevens, and C.-S. Liang Selegiline improves cardiac sympathetic terminal function and beta -adrenergic responsiveness in heart failure Am J Physiol Heart Circ Physiol, September 1, 2000; 279(3): H1283 - H1290. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Azevedo, G. E. Newton, J. S. Floras, and J. D. Parker Reducing Cardiac Filling Pressure Lowers Norepinephrine Spillover in Patients With Chronic Heart Failure Circulation, May 2, 2000; 101(17): 2053 - 2059. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |